| Name | Title | Contact Details |
|---|
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
The California Poison Control System (CPCS) is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Zutron Medical is a Kansas City, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Baldwin Emergency Medical Service is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fallon Ambulance Service was founded in 1936 by James Fallon Sr. and remains a family operated business to this day. Fallon Ambulance employs more than 525 personnel, including 125 Paramedics and 375 EMTs, and operates 115 vehicles. The company provides